AR and metabolic disease: Our results indicate that different dosages of SBA or positive controls can regulate the downstream products by inhibiting the level of AR protein and protect ARPE-19 from the metabolic disorder and oxidative unbalance caused by high glucose, which is conducive to maintaining the function of the RPE cell layer.